|
Ä«Å×°í¸®
|
ÀǾàǰ
|
|
Á¦¸ñ
|
[½ÄǰÀǾàǰ¾ÈÀüó] °³ÀÎ ¸ÂÃãÇü ½Å»ýÇ׿ø Ä¡·áÁ¦ °³¹ß½Ã °í·Á»çÇ× °¡À̵å¶óÀÎ(¹Î¿øÀξȳ»¼)(¿µ¹®º»)
|
|
ÀÛ¼ºÀÚ
|
kbihealth
|
|
µî·ÏÀÏ
|
2024-10-04
|
|
Á¶È¸¼ö
|
227
|
½ÄǰÀǾàǰ¾ÈÀüÆò°¡¿ø¿¡¼´Â °³ÀÎ ¸ÂÃãÇü ½Å»ýÇ׿ø Ä¡·áÁ¦ °³¹ß½Ã °í·Á»çÇ× °¡À̵å¶óÀÎ(¹Î¿øÀξȳ»¼)(¿µ¹®º»)À» °³Á¤/¹ß°£ÇÏ¿´À¸´Ï °ü·Ã ¾÷¹«¿¡ Âü°íÇϽñ⠹ٶø´Ï´Ù. (Considerations on the Development of Personalized Neoantigen-Targeted Therapy Products)
°¨»çÇÕ´Ï´Ù.
|
|
÷ºÎÆÄÀÏ
|
°³ÀÎ ¸ÂÃãÇü ½Å»ýÇ׿ø Ä¡·áÁ¦ °³¹ß½Ã °í·Á»çÇ× °¡À̵å¶óÀÎ(¹Î¿øÀξȳ»¼)(¿µ¹®º»).pdf

´Ù¿î·Îµå : 143
|